<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1916" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="904" end="909"/>
    <type:ORR xmi:id="25" sofa="6" begin="1272" end="1275"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="1171" end="1181"/>
    <type:PFSMean xmi:id="29" sofa="6" begin="1299" end="1309"/>
    <type:OSMean xmi:id="21" sofa="6" begin="1186" end="1195"/>
    <type:OSMean xmi:id="33" sofa="6" begin="1329" end="1338"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND: Sequential treatment with azacitidine can induce re-expression of&#13;&#10;epigenetically silenced genes through genomic DNA hypomethylation and reverse&#13;&#10;carboplatin resistance of epithelial ovarian cancer cells. A phase 1b-2a clinical&#13;&#10;trial of this sequential combination of azacitidine and carboplatin was initiated&#13;&#10;in patients with platinum-resistant or platinum-refractory epithelial ovarian&#13;&#10;cancer.&#13;&#10;METHODS: Patients with pathologically confirmed intermediate-grade or high-grade &#13;&#10;epithelial ovarian cancer who developed disease progression within 6 months&#13;&#10;(resistant disease, n = 18 patients) or during a platinum-based therapy&#13;&#10;(refractory disease, n = 12 patients) were eligible. All patients had measurable &#13;&#10;disease.&#13;&#10;RESULTS: Thirty patients received a total of 163 cycles of treatment. This&#13;&#10;regimen produced 1 complete response, 3 partial responses (overall response rate &#13;&#10;[ORR], 13.8%), and 10 cases of stable disease among 29 evaluable patients. For&#13;&#10;those patients who achieved clinical benefits, the median duration of the&#13;&#10;treatment was 7.5 months. The median progression-free survival (PFS) and overall &#13;&#10;survival (OS) for all patients were 3.7 months and 14 months, respectively.&#13;&#10;Patients with platinum-resistant disease achieved an ORR of 22%, with a median&#13;&#10;PFS of 5.6 months and a median OS of 23 months. The predominant toxicities were&#13;&#10;fatigue and myelosuppression. Correlative studies indicated that DR4 methylation &#13;&#10;in peripheral blood leukocytes was decreased during treatment in 3 of 4 objective&#13;&#10;responders (75%), but in only 5 of 13 nonresponders (38%).&#13;&#10;CONCLUSIONS: To the authors' knowledge, the results of the current study provide &#13;&#10;the first clinical evidence that a hypomethylating agent may partially reverse&#13;&#10;platinum resistance in patients with ovarian cancer. Further clinical evaluation &#13;&#10;of hypomethylating agents in combination with carboplatin is warranted."/>
    <cas:View sofa="6" members="1 13 25 17 29 21 33"/>
</xmi:XMI>
